Loading...

Grifols, S.A.

GRFS•NASDAQ
Healthcare
Drug Manufacturers - General
$10.10
$0.16(1.61%)

Grifols, S.A. (GRFS) Stock Overview

Explore Grifols, S.A.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 70.7/100

Key Financials

Market Cap8.7B
P/E Ratio30.66
EPS (TTM)$0.27
ROE0.03%
Fundamental Analysis

AI Price Forecasts

1 Week$8.72
1 Month$8.63
3 Months$7.47
1 Year Target$7.53

GRFS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Grifols, S.A. (GRFS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 67.92, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $7.53.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 30.66 and a market capitalization of 8.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;